
Inovio Pharmaceuticals Inc (AKA: Inovio Biomedical Corporation ~ BTX Inc ~ Genetronics Biomedical LTD ~ Biotechno) Profile last edited on: 4/15/2021
CAGE: 43MD0
UEI: CE2NDNHN33X5
Business Identifier: DNA immunotherapies for HPV, solid tumors and infectious diseases Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 04
County: Montgomery
Congr. District: 04
County: Montgomery
Public Profile
With facilities in California but headquartered in Pennsylvania, Inovio Pharmaceuticals Inc, (NASDAQ:INO) -- formerly known as Inovio Biomedical Corporation and before that as Genetronics Inc -- is a biomedical company developing drug and gene delivery systems that use electroporation therapy (EPT) to deliver drugs and genes into cells. Stimulating the bodys immune system remains one of the most promising approaches to addressing the unmet needs of cancers, HIV, hepatitis C virus, and other chronic infectious diseases. The firm has developed a synthetic vaccine technology platform that is progressively showing potential to prevent and treat life-altering diseases. Using their synthetic DNA vaccine technology, Inovio is developing a new generation of potential vaccines against infectious disease. This technology enables the design of synthetic vaccines targeting multiple antigens of a disease with the genetic makeup of the antigen based on different strains, to help provide broader preemptive protection against the mutations that will inevitably occur. Partners and collaborators include Roche, the University of Pennsylvania, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, US Dept. of Homeland Security, and University of Manitoba.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
250-500Revenue Range
20M-50MVC funded?
YesPublic/Private
Publicly TradedStock Info
NASDAQ : INOIP Holdings
75-99Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2011 | 2 | Army | $834,931 | |
Project Title: Multiagent Synthetic DNA Vaccines Delivered by Noninvasive Electroporation | ||||
2004 | 1 | NIH | $102,865 | |
Project Title: Ex vivo venous gene delivery by pulsed electric-fields | ||||
1999 | 1 | NIH | $99,995 | |
Project Title: In Vivo Skin Targeted Gene Therapy By Electroporation | ||||
1998 | 1 | NIH | $94,301 | |
Project Title: Electrically Enhanced Transdermal Delivery Of Calcitonin | ||||
1998 | 2 | NIH | $691,052 | |
Project Title: Novel and Efficient Method of Anticancer Drug Delivery |
Key People / Management
J Joseph Kim -- Founder, President; Chief Executive Officer; Director
Mark Bagarazzi -- Chief Medical Officer
Prakash Bhuyan -- Vice President, Clinical Development
Ej Brandreth -- Vice President, Quality Assurance
Kate Broderick
Lois Crandell -- former President
Ildiko Csiki -- Vice President, Clinical Development
Nagendu B Dev
Sukhendu B Dev
Gunter A Hofmann
Laurent Humeau -- Senior Vice President, Research and Development
Daniel Jordan -- Vice President, Device Manufacturing Operations
Robert J Juba Jr -- Vice President, Biological Manufacturing and Clinical Supply Management
Stephen Kemmerrer -- Vice President of Engineering Operations
Peter Kies -- Chief Financial Officer
Jennifer Laux -- Vice President, Commercial
Jessica C Lee -- Vice President, Clinical Operations and Global Integration
Niranjan Y Sardesai -- Chief Operations Office
Ami Shah Brown -- Vice President, Regulatory Affairs
Jacqueline Shea -- Chief Operating Officer
Jeffrey Skolnik -- Vice President, Clinical Development
Scott M White -- Vice President, Clinical Development
Mark Bagarazzi -- Chief Medical Officer
Prakash Bhuyan -- Vice President, Clinical Development
Ej Brandreth -- Vice President, Quality Assurance
Kate Broderick
Lois Crandell -- former President
Ildiko Csiki -- Vice President, Clinical Development
Nagendu B Dev
Sukhendu B Dev
Gunter A Hofmann
Laurent Humeau -- Senior Vice President, Research and Development
Daniel Jordan -- Vice President, Device Manufacturing Operations
Robert J Juba Jr -- Vice President, Biological Manufacturing and Clinical Supply Management
Stephen Kemmerrer -- Vice President of Engineering Operations
Peter Kies -- Chief Financial Officer
Jennifer Laux -- Vice President, Commercial
Jessica C Lee -- Vice President, Clinical Operations and Global Integration
Niranjan Y Sardesai -- Chief Operations Office
Ami Shah Brown -- Vice President, Regulatory Affairs
Jacqueline Shea -- Chief Operating Officer
Jeffrey Skolnik -- Vice President, Clinical Development
Scott M White -- Vice President, Clinical Development